Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Clinical utilization of cord blood over human health: experience of stem cell transplantation and cell therapy using cord blood in Korea

  • Lee, Young-Ho (Department of Pediatrics, Hanyang University College of Medicine)
  • Received : 2013.09.23
  • Accepted : 2014.02.07
  • Published : 2014.03.15
Download PDF
⟨ Previous Next ⟩

Abstract

Cord blood (CB) has been used as an important and ethical source for hematopoietic stem cell transplantation (SCT) as well as cell therapy by manufacturing mesenchymal stem cell, induced pleuripotential stem cell or just isolating mononuclear cell from CB. Recently, the application of cell-based therapy using CB has expanded its clinical utility, particularly, by using autologous CB in children with refractory diseases. For these purposes, CB has been stored worldwide since mid-1990. In this review, I would like to briefly present the historical development of clinical uses of CB in the fields of SCT and cell therapy, particularly to review the experiences in Korea. Furthermore, I would touch the recent banking status of CB.

Keywords

References

  1. Wagner JE, Kernan NA, Steinbuch M, Broxmeyer HE, Gluckman E. Allogeneic sibling umbilical-cord-blood transplantation in children with malignant and non-malignant disease. Lancet 1995; 346:214-9. https://doi.org/10.1016/S0140-6736(95)91268-1
  2. Boelens JJ. Trends in haematopoietic cell transplantation for inborn errors of metabolism. J Inherit Metab Dis 2006;29:413-20. https://doi.org/10.1007/s10545-005-0258-8
  3. Zhang X, Hirai M, Cantero S, Ciubotariu R, Dobrila L, Hirsh A, et al. Isolation and characterization of mesenchymal stem cells from human umbilical cord blood: reevaluation of critical factors for successful isolation and high ability to proliferate and differentiate to chondrocytes as compared to mesenchymal stem cells from bone marrow and adipose tissue. J Cell Biochem 2011;112:1206-18. https://doi.org/10.1002/jcb.23042
  4. Broxmeyer HE, Lee MR, Hangoc G, Cooper S, Prasain N, Kim YJ, et al. Hematopoietic stem/progenitor cells, generation of induced pluripotent stem cells, and isolation of endothelial progenitors from 21- to 23.5-year cryopreserved cord blood. Blood 2011;117:4773-7. https://doi.org/10.1182/blood-2011-01-330514
  5. Fan CG, Zhang QJ, Tang FW, Han ZB, Wang GS, Han ZC. Human umbilical cord blood cells express neurotrophic factors. Neurosci Lett 2005;380:322-5. https://doi.org/10.1016/j.neulet.2005.01.070
  6. Bachstetter AD, Pabon MM, Cole MJ, Hudson CE, Sanberg PR, Willing AE, et al. Peripheral injection of human umbilical cord blood stimulates neurogenesis in the aged rat brain. BMC Neurosci 2008;9:22. https://doi.org/10.1186/1471-2202-9-22
  7. Xiao J, Nan Z, Motooka Y, Low WC. Transplantation of a novel cell line population of umbilical cord blood stem cells ameliorates neurological deficits associated with ischemic brain injury. Stem Cells Dev 2005;14:722-33. https://doi.org/10.1089/scd.2005.14.722
  8. Broxmeyer HE, Douglas GW, Hangoc G, Cooper S, Bard J, English D, et al. Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. Proc Natl Acad Sci U S A 1989;86:3828-32. https://doi.org/10.1073/pnas.86.10.3828
  9. Gluckman E, Broxmeyer HA, Auerbach AD, Friedman HS, Douglas GW, Devergie A, et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med 1989;321:1174-8. https://doi.org/10.1056/NEJM198910263211707
  10. Wagner JE, Broxmeyer HE, Byrd RL, Zehnbauer B, Schmeckpeper B, Shah N, et al. Transplantation of umbilical cord blood after myeloablative therapy: analysis of engraftment. Blood 1992;79:1874-81.
  11. Kohli-Kumar M, Shahidi NT, Broxmeyer HE, Masterson M, Delaat C, Sambrano J, et al. Haemopoietic stem/progenitor cell transplant in Fanconi anaemia using HLA-matched sibling umbilical cord blood cells. Br J Haematol 1993;85:419-22. https://doi.org/10.1111/j.1365-2141.1993.tb03192.x
  12. Barker JN, Weisdorf DJ, Wagner JE. Creation of a double chimera after the transplantation of umbilical-cord blood from two partially matched unrelated donors. N Engl J Med 2001;344:1870-1.
  13. Shpall EJ, Quinones R, Giller R, Zeng C, Baron AE, Jones RB, et al. Transplantation of ex vivo expanded cord blood. Biol Blood Marrow Transplant 2002;8:368-76. https://doi.org/10.1053/bbmt.2002.v8.pm12171483
  14. Frassoni F, Gualandi F, Podesta M, Raiola AM, Ibatici A, Piaggio G, et al. Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. Lancet Oncol 2008;9:831-9. https://doi.org/10.1016/S1470-2045(08)70180-3
  15. Brunstein CG, Barker JN, Weisdorf DJ, Defor TE, McKenna D, Chong SY, et al. Intra-BM injection to enhance engraftment after myeloablative umbilical cord blood transplantation with two partially HLA-matched units. Bone Marrow Transplant 2009;43:935-40. https://doi.org/10.1038/bmt.2008.417
  16. Gonzalo-Daganzo R, Regidor C, Martin-Donaire T, Rico MA, Bautista G, Krsnik I, et al. Results of a pilot study on the use of thirdparty donor mesenchymal stromal cells in cord blood transplantation in adults. Cytotherapy 2009;11:278-88. https://doi.org/10.1080/14653240902807018
  17. Brunstein CG, Barker JN, Weisdorf DJ, DeFor TE, Miller JS, Blazar BR, et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood 2007;110:3064-70. https://doi.org/10.1182/blood-2007-04-067215
  18. MacMillan ML, Weisdorf DJ, Brunstein CG, Cao Q, DeFor TE, Verneris MR, et al. Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors. Blood 2009;113:2410-5. https://doi.org/10.1182/blood-2008-07-163238
  19. Rodrigues CA, Sanz G, Brunstein CG, Sanz J, Wagner JE, Renaud M, et al. Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 2009;27:256-63. https://doi.org/10.1200/JCO.2007.15.8865
  20. Verneris MR, Brunstein CG, Barker J, MacMillan ML, DeFor T, McKenna DH, et al. Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. Blood 2009;114:4293-9. https://doi.org/10.1182/blood-2009-05-220525
  21. Goldstein G, Elhasid R, Bielorai B, Shimoni A, Yerushalmi R, Kassis I, et al. Adults requiring cord blood transplants but have insufficient cell doses from a single cord blood unit can receive two units with successful engraftment kinetics similar to those of children receiving a single unit. Leuk Lymphoma 2011;52:635-41. https://doi.org/10.3109/10428194.2010.548109
  22. Brunstein CG, Gutman JA, Weisdorf DJ, Woolfrey AE, Defor TE, Gooley TA, et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood 2010;116:4693-9. https://doi.org/10.1182/blood-2010-05-285304
  23. Ballen KK, Spitzer TR, Yeap BY, McAfee S, Dey BR, Attar E, et al. Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant 2007;13:82-9.
  24. Scaradavou A, Smith KM, Hawke R, Schaible A, Abboud M, Kernan NA, et al. Cord blood units with low CD34+ cell viability have a low probability of engraftment after double unit transplantation. Biol Blood Marrow Transplant 2010;16:500-8. https://doi.org/10.1016/j.bbmt.2009.11.013
  25. Haspel RL, Kao G, Yeap BY, Cutler C, Soiffer RJ, Alyea EP, et al. Preinfusion variables predict the predominant unit in the setting of reduced-intensity double cord blood transplantation. Bone Marrow Transplant 2008;41:523-9. https://doi.org/10.1038/sj.bmt.1705933
  26. Delaney C, Heimfeld S, Brashem-Stein C, Voorhies H, Manger RL, Bernstein ID. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med 2010;16:232-6. https://doi.org/10.1038/nm.2080
  27. De Lima M, Robinson S, McMannis JD, Alousi AM, Saliba RM, Munsell M, et al. Mesenchymal stem cell based cord blood expansion leads to rapid engraftment of platelets and neutrophils. Blood 2010; 116:164.
  28. Ho VT, Soiffer RJ. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 2001;98:3192-204. https://doi.org/10.1182/blood.V98.12.3192
  29. Marmont AM, Horowitz MM, Gale RP, Sobocinski K, Ash RC, van Bekkum DW, et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991;78:2120-30.
  30. Barker JN, Weisdorf DJ, DeFor TE, Blazar BR, McGlave PB, Miller JS, et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 2005;105:1343-7.
  31. Gutman JA, Turtle CJ, Manley TJ, Heimfeld S, Bernstein ID, Riddell SR, et al. Single-unit dominance after double-unit umbilical cord blood transplantation coincides with a specific CD8+ T-cell response against the nonengrafted unit. Blood 2010;115:757-65. https://doi.org/10.1182/blood-2009-07-228999
  32. Kanda J, Rizzieri DA, Gasparetto C, Long GD, Chute JP, Sullivan KM, et al. Adult dual umbilical cord blood transplantation using myeloablative total body irradiation (1350 cGy) and fludarabine conditioning. Biol Blood Marrow Transplant 2011;17:867-74. https://doi.org/10.1016/j.bbmt.2010.09.009
  33. Eldjerou LK, Chaudhury S, Baisre-de Leon A, He M, Arcila ME, Heller G, et al. An in vivo model of double-unit cord blood transplantation that correlates with clinical engraftment. Blood 2010; 116:3999-4006. https://doi.org/10.1182/blood-2010-03-276212
  34. Barker JN, Scaradavou A, Stevens CE. Combined effect of total nucleated cell dose and HLA match on transplantation outcome in 1061 cord blood recipients with hematologic malignancies. Blood 2010;115:1843-9. https://doi.org/10.1182/blood-2009-07-231068
  35. Cutler C, Kim HT, Sun L, Sese D, Glotzbecker B, Armand P, et al. Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. Blood 2011;118:6691-7. https://doi.org/10.1182/blood-2011-05-355263
  36. Ruggeri A, Rocha V, Masson E, Labopin M, Cunha R, Absi L, et al. Impact of donor-specific anti-HLA antibodies on graft failure and survival after reduced intensity conditioning-unrelated cord blood transplantation: a Eurocord, Société Francophone d'Histocompatibilité et d'Immunogénétique (SFHI) and Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) analysis. Haematologica 2013;98:1154-60. https://doi.org/10.3324/haematol.2012.077685
  37. Takanashi M, Atsuta Y, Fujiwara K, Kodo H, Kai S, Sato H, et al. The impact of anti-HLA antibodies on unrelated cord blood transplantations. Blood 2010;116:2839-46. https://doi.org/10.1182/blood-2009-10-249219
  38. Rocha V, Spellman S, Zhang MJ, Ruggeri A, Purtill D, Brady C, et al. Effect of HLA-matching recipients to donor noninherited maternal antigens on outcomes after mismatched umbilical cord blood transplantation for hematologic malignancy. Biol Blood Marrow Transplant 2012;18:1890-6. https://doi.org/10.1016/j.bbmt.2012.07.010
  39. van Rood JJ, Stevens CE, Smits J, Carrier C, Carpenter C, Scaradavou A. Reexposure of cord blood to noninherited maternal HLA antigens improves transplant outcome in hematological malignancies. Proc Natl Acad Sci U S A 2009;106:19952-7. https://doi.org/10.1073/pnas.0910310106
  40. Lee YH, Cho NC, Je KH, Han H, Han JY, Kim JS, et al. Successful sibling cord blood stem cell transplantation for relapsed acute mixed lineage leukemia. Korean J Hematol 1999;34:471-6.
  41. Kang HJ, Yoo KH, Lee JW, Kim H, Lee SH, Sung KW, et al. Double umbilical cord blood transplantation for children and adolescents. Ann Hematol 2010;89:1035-44. https://doi.org/10.1007/s00277-010-0985-2
  42. Park M, Lee YH, Lee SH, Yoo KH, Sung KW, Koo HH, et al. Current status of unrelated cord blood transplantation in Korea. Korean J Hematol 2012:47(Suppl 1);63.
  43. Takahashi N, Uehara R, Kobayashi M, Yada Y, Koike Y, Kawamata R, et al. Cytokine profiles of seventeen cytokines, growth factors and chemokines in cord blood and its relation to perinatal clinical findings. Cytokine 2010;49:331-7. https://doi.org/10.1016/j.cyto.2009.11.024
  44. Mathieu M, Bartunek J, El Oumeiri B, Touihri K, Hadad I, Thoma P, et al. Cell therapy with autologous bone marrow mononuclear stem cells is associated with superior cardiac recovery compared with use of nonmodified mesenchymal stem cells in a canine model of chronic myocardial infarction. J Thorac Cardiovasc Surg 2009;138:646-53. https://doi.org/10.1016/j.jtcvs.2008.12.031
  45. Chen J, Sanberg PR, Li Y, Wang L, Lu M, Willing AE, et al. Intravenous administration of human umbilical cord blood reduces behavioral deficits after stroke in rats. Stroke 2001;32:2682-8. https://doi.org/10.1161/hs1101.098367
  46. Haller MJ, Wasserfall CH, McGrail KM, Cintron M, Brusko TM, Wingard JR, et al. Autologous umbilical cord blood transfusion in very young children with type 1 diabetes. Diabetes Care 2009;32: 2041-6. https://doi.org/10.2337/dc09-0967
  47. Liao Y, Cotten M, Tan S, Kurtzberg J, Cairo MS. Rescuing the neonatal brain from hypoxic injury with autologous cord blood. Bone Marrow Transplant 2013;48:890-900. https://doi.org/10.1038/bmt.2012.169
  48. Lv YT, Zhang Y, Liu M, Qiuwaxi JN, Ashwood P, Cho SC, et al. Transplantation of human cord blood mononuclear cells and umbilical cord-derived mesenchymal stem cells in autism. J Transl Med 2013;11:196. https://doi.org/10.1186/1479-5876-11-196
  49. Lee YH, Choi KV, Moon JH, Jun HJ, Kang HR, Oh SI, et al. Safety and feasibility of countering neurological impairment by intravenous administration of autologous cord blood in cerebral palsy. J Transl Med 2012;10:58. https://doi.org/10.1186/1479-5876-10-58
  50. Momin EN, Mohyeldin A, Zaidi HA, Vela G, Quinones-Hinojosa A. Mesenchymal stem cells: new approaches for the treatment of neurological diseases. Curr Stem Cell Res Ther 2010;5:326-44. https://doi.org/10.2174/157488810793351631
  51. Haller MJ, Wasserfall CH, Hulme MA, Cintron M, Brusko TM, McGrail KM, et al. Autologous umbilical cord blood transfusion in young children with type 1 diabetes fails to preserve C-peptide. Diabetes Care 2011;34:2567-9. https://doi.org/10.2337/dc11-1406
  52. ClinicalTrials.gov. Kurtzberg J. A randomized study of autologous umbilical cord blood reinfusion in children with cerebral palsy [Internet]. Bethesda: ClinicalTrials.gov; [cited 2013 Sep 17]. Available from: http://clinicaltrials.gov/show/NCT01147653.
  53. Sun J, Allison J, McLaughlin C, Sledge L, Waters-Pick B, Wease S, et al. Differences in quality between privately and publicly banked umbilical cord blood units: a pilot study of autologous cord blood infusion in children with acquired neurologic disorders. Transfusion 2010;50:1980-7. https://doi.org/10.1111/j.1537-2995.2010.02720.x
  54. Min K, Song J, Kang JY, Ko J, Ryu JS, Kang MS, et al. Umbilical cord blood therapy potentiated with erythropoietin for children with cerebral palsy: a double-blind, randomized, placebo-controlled trial. Stem Cells 2013;31:581-91. https://doi.org/10.1002/stem.1304
  55. Lee YH. The prospect of the government management for cord blood in Korea: at the time of enactment of the Cord blood management and research act. Korean J Hematol 2010;45:1-2. https://doi.org/10.5045/kjh.2010.45.1.1
  56. Lee YH, Kim JY, Mun YC, Koo HH. A proposal for improvement in the utilization rate of banked cord blood. Blood Res 2013;48:5-7. https://doi.org/10.5045/br.2013.48.1.5

Cited by

  1. Predictive analytics and cord blood banking: toward utilization-based unit selection vol.23, pp.7, 2021, https://doi.org/10.1016/j.jcyt.2021.01.002
  2. DNA barcode to trace the development and differentiation of cord blood stem cells (Review) vol.24, pp.6, 2014, https://doi.org/10.3892/mmr.2021.12489